AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress
AVROBIO, Inc. (AVRO)
Last avrobio, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.avrobio.com/investor-relations
Company Research
Source: Business Wire
New safety data to be reported from clinical trials in Fabry disease and Gaucher disease type 1 CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will present new safety data from AVROBIO’s clinical trials in Fabry disease and Gaucher disease type 1 at the virtual 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Oct. 19-22, 2021.Clinical and preclinical data from across the company’s pipeline of lysosomal disorder gene therapy programs will be included in two oral presentations and five poster presentations. Additionally, AVROBIO will sponsor a symposium on Wednesday, Oct. 20, 2021, on “Advancing the patient experience during ex vivo lentiviral gene therapy for lysosomal disorders.”The presentations are listed below, and the full program is available online at the ESGCT website.ORAL PRESENTATIONS:“High-res
Show less
Read more
Impact Snapshot
Event Time:
AVRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVRO alerts
High impacting AVROBIO, Inc. news events
Weekly update
A roundup of the hottest topics
AVRO
News
- Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure [Yahoo! Finance]Yahoo! Finance
- Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart FailureBusiness Wire
- SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CHRD, KAMN, CTLT, AVROAccesswire
- Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law FirmPR Newswire
- Tectonic Therapeutic Announces Participation at Investor Conferences in MarchBusiness Wire
AVRO
Sec Filings
- 4/15/24 - Form S-4/A
- 4/4/24 - Form 425
- 3/26/24 - Form S-4/A
- AVRO's page on the SEC website